本研究旨在探讨造血干细胞移植（HSCT）后不同时间点患者报告的项目与长期生存之间的关联。我们对 144 名同种异体 HSCT 患者进行了一项研究，对他们进行了移植后 5 年的随访。移植前和移植后 1、3、6、12、18、36 和 60 个月收集癌症治疗功能评估-骨髓移植 (FACT-BMT) 问卷的数据。还评估了人口学特征和生存状况。 144例患者的5年总生存期（OS）、无进展生存期（PFS）、非复发死亡率（NRM）和无移植物抗宿主病（无移植物抗宿主病）（ GRFS）率分别为 65%、48%、17% 和 36%。健康相关生活质量 (HRQOL) 在 5 年内呈现波动模式。使用潜在类别混合模型，根据 60 个月随访期间患者的身体健康 (PWB) 评分将患者分为两组。 1 级的 PWB 分数最初较低，但随着时间的推移逐渐上升。相比之下，2 级保持较高的 PWB 分数，并随着时间的推移略有增加。 Kaplan-Meier 生存分析显示，1 类具有更好的 OS（70.9% vs. 52.9%，p = 0.021）、PFS（60.5% vs. 41.2%，p = 0.039）和 GRFS（35.1% vs. 29.3%，p = 0.035) 与第 2 类相比。HSCT 后初始 PWB 评分较高的患者表现出长期生存结果的改善。 PWB 评分可以作为 HSCT 预后的有价值的预测指标。© 2024 作者。约翰·威利出版的癌症医学

This study aimed to explore the association between patient-reported items at different time points after hematopoietic stem cell transplantation (HSCT) and long-term survival.We conducted a study with 144 allogeneic HSCT patients, following them for 5 years post-transplantation. Data from the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) questionnaire were collected before transplantation and at 1, 3, 6, 12, 18, 36, and 60 months after transplantation. Demographic characteristics and survival status were also assessed.Among the 144 cases, the 5-year overall survival (OS), progression-free survival (PFS), non-relapse mortality (NRM), and graft-versus-host disease-free (GRFS) rates were 65%, 48%, 17%, and 36% respectively. Health-related quality of life (HRQOL) showed a fluctuating pattern over 5 years. Using a latent class mixed model, patients were classified into two groups based on their physical well-being (PWB) scores during the 60-month follow-up. Class 1 had initially lower PWB scores, which gradually increased over time. In contrast, Class 2 maintained higher PWB scores with slight increases over time. Kaplan-Meier survival analysis revealed that Class 1 had better OS (70.9% vs. 52.9%, p = 0.021), PFS (60.5% vs. 41.2%, p = 0.039), and GRFS (35.1% vs. 29.3%, p = 0.035) compared to Class 2.Patients who had higher initial PWB scores after HSCT demonstrated improved long-term survival outcomes. The PWB score could serve as a valuable predictor for the prognosis of HSCT.© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.